Paricalcitol Side Effects
The most clinically significant side effect of paricalcitol is hypercalcemia, which occurred in 22.6-43.3% of patients in major clinical trials, representing a substantially higher risk than placebo (0.9-3.3%). 1
Primary Safety Concerns
Hypercalcemia (Most Important)
- Hypercalcemia is the predominant adverse effect requiring close monitoring 2
- In the PRIMO trial: 22.6% of paricalcitol patients vs. 0.9% placebo developed hypercalcemia 1
- In the OPERA trial: 43.3% of paricalcitol patients vs. 3.3% placebo developed hypercalcemia (serum calcium >10.2 mg/dL) 1
- Mean serum calcium increased by 0.08 mmol/L (0.32 mg/dL) with paricalcitol treatment 1
- 70% of hypercalcemic episodes occurred in patients taking concomitant calcium-based phosphate binders 1
- Hypercalcemia can be corrected by stopping calcium binders without discontinuing paricalcitol 1
Acute Hypercalcemia Complications
- Increased risk of cardiac arrhythmias 2
- Increased risk of seizures 2
- Potentiation of digitalis toxicity - requires increased monitoring when used with digoxin 2
- Severe hypercalcemia may require emergency attention 2
Chronic Hypercalcemia Complications
Symptoms of Hypercalcemia to Monitor
Patients should be counseled to report: 2
- Feeling tired
- Difficulty thinking clearly
- Loss of appetite
- Nausea and vomiting
- Constipation
- Increased thirst
- Increased urination
- Weight loss
Secondary Adverse Effects
Adynamic Bone Disease
- Occurs when PTH levels are over-suppressed to abnormally low levels 2
- Results in increased fracture risk 2
- Requires monitoring of intact PTH levels to avoid over-suppression 2
Hypersensitivity Reactions
- Angioedema (including laryngeal edema) 2
- Urticaria 2
- Paricalcitol is contraindicated in patients with known hypersensitivity 2
Metabolic Effects
- Hypercalciuria and hyperphosphatemia - particularly when combined with high calcium and phosphate intake 2
- Elevated calcium-phosphorus product 3, 4
- Decreased glomerular filtration rate (mean decrease -3.15 mL/min) 5
- Elevated serum creatinine (mean increase 0.93 mg/dL) 5
Common Adverse Events
From clinical trials, the following were reported as possibly, probably, or definitely related to paricalcitol: 3
- Nausea/vomiting
- Metallic taste
- Chills
- Fever
- Sepsis
- Palpitations
- Dry mouth
- Gastrointestinal bleeding
- Edema
- Light-headedness
- Pneumonia
Critical Monitoring Requirements
Frequency of Monitoring
- When initiating or adjusting dose: measure serum calcium twice weekly 2
- Once maintenance dose established: measure serum calcium at least monthly 2
- Monitor intact PTH every 2-4 weeks after initiation or dose adjustment 2
- Increased monitoring required when used with digitalis compounds 2
Management of Hypercalcemia
- Reduce dose or discontinue paricalcitol until serum calcium normalizes 2
- Consider stopping calcium-based phosphate binders first 1
- Restart at reduced dose after laboratory values normalize 2
Contraindications
Paricalcitol is absolutely contraindicated in: 2
- Pre-existing hypercalcemia
- Vitamin D toxicity
- Known hypersensitivity to paricalcitol or inactive ingredients
Important Clinical Context
The KDIGO 2017 guidelines now recommend against routine use of paricalcitol in CKD stages 3a-5 not on dialysis due to unfavorable risk-benefit ratio, reserving it only for severe and progressive secondary hyperparathyroidism 1. This recommendation change was driven by the PRIMO and OPERA trials showing significant hypercalcemia risk without demonstrable benefits on patient-centered outcomes like cardiac structure or mortality 1.